Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that the company will present four posters at the PHA 2026 International PH Conference and Scientific Sessions taking place June 11-14 in Dallas.
Liquidia will present data from Cohort A of its ASCENT study of YUTREPIA® (treprostinil) inhalation powder, including patient-reported cough outcomes in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) over 24 weeks of treatment. The company will also present new data and analyses examining the role of pharmacists within PH care teams and the mental health burden experienced by caregivers of patients with PH. In addition, Liquidia will present an encore of previously reported safety and exploratory efficacy data from the ASCENT study.
Dr. Rajeev Saggar, Liquidia Chief Medical Officer, said: “We are proud to share our research with the patients and caregivers at the center of the pulmonary hypertension community. From listening to patients describe their own experience with treatment to understanding the burden carried by caregivers and the role of the care teams who support them, this work reflects our commitment to the people living with this condition every day.”
All posters will be presented from 4 to 5 p.m. CDT Thursday, June 11, in the exhibition hall. Upon presentation, each publicly presented poster will be available on the publications page of Liquidia’s website at https://liquidia.com/publications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.